These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 23177288)

  • 1. Non-nucleoside analogue polymerase inhibitors in development.
    Pockros PJ
    Clin Liver Dis; 2013 Feb; 17(1):123-8. PubMed ID: 23177288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future directions in therapy for chronic hepatitis C.
    Jensen DM; Ascione A
    Antivir Ther; 2008; 13 Suppl 1():31-6. PubMed ID: 18432161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and SAR of novel 1,1-dialkyl-2(1H)-naphthalenones as potent HCV polymerase inhibitors.
    Bosse TD; Larson DP; Wagner R; Hutchinson DK; Rockway TW; Kati WM; Liu Y; Masse S; Middleton T; Mo H; Montgomery D; Jiang W; Koev G; Kempf DJ; Molla A
    Bioorg Med Chem Lett; 2008 Jan; 18(2):568-70. PubMed ID: 18068361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valopicitabine dihydrochloride:a specific polymerase inhibitor of hepatitis C virus.
    Toniutto P; Fabris C; Bitetto D; Fornasiere E; Rapetti R; Pirisi M
    Curr Opin Investig Drugs; 2007 Feb; 8(2):150-8. PubMed ID: 17328231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges.
    Li H; Shi ST
    Future Med Chem; 2010 Jan; 2(1):121-41. PubMed ID: 21426049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-nucleoside inhibitors of the HCV polymerase.
    Sarisky RT
    J Antimicrob Chemother; 2004 Jul; 54(1):14-6. PubMed ID: 15190019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of hepatitis C virus polymerase: synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazines.
    Wagner R; Larson DP; Beno DW; Bosse TD; Darbyshire JF; Gao Y; Gates BD; He W; Henry RF; Hernandez LE; Hutchinson DK; Jiang WW; Kati WM; Klein LL; Koev G; Kohlbrenner W; Krueger AC; Liu J; Liu Y; Long MA; Maring CJ; Masse SV; Middleton T; Montgomery DA; Pratt JK; Stuart P; Molla A; Kempf DJ
    J Med Chem; 2009 Mar; 52(6):1659-69. PubMed ID: 19226162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on combinations of DAAs with and without pegylated-interferon and ribavirin: triple and quadruple therapy more than doubles SVR.
    Martel-Laferrière V; Dieterich DT
    Clin Liver Dis; 2013 Feb; 17(1):93-103. PubMed ID: 23177285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminothiazole inhibitors of HCV RNA polymerase.
    Shipps GW; Deng Y; Wang T; Popovici-Muller J; Curran PJ; Rosner KE; Cooper AB; Girijavallabhan V; Butkiewicz N; Cable M
    Bioorg Med Chem Lett; 2005 Jan; 15(1):115-9. PubMed ID: 15582422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrazolo[1,5-a]pyrimidine-based inhibitors of HCV polymerase.
    Popovici-Muller J; Shipps GW; Rosner KE; Deng Y; Wang T; Curran PJ; Brown MA; Siddiqui MA; Cooper AB; Duca J; Cable M; Girijavallabhan V
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6331-6. PubMed ID: 19819138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moving beyond interferon alfa: investigational drugs for hepatitis C virus infection.
    Wyles DL
    Top HIV Med; 2010; 18(4):132-6. PubMed ID: 21107012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological characterization of B-ring amino analogues of potent benzothiadiazine hepatitis C virus polymerase inhibitors.
    Randolph JT; Flentge CA; Huang PP; Hutchinson DK; Klein LL; Lim HB; Mondal R; Reisch T; Montgomery DA; Jiang WW; Masse SV; Hernandez LE; Henry RF; Liu Y; Koev G; Kati WM; Stewart KD; Beno DW; Molla A; Kempf DJ
    J Med Chem; 2009 May; 52(10):3174-83. PubMed ID: 19402666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New antivirals against hepatitis C virus].
    Kato N; Muroyama R; Goto K
    Nihon Rinsho; 2012 Apr; 70(4):664-70. PubMed ID: 22568151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future hepatitis C virus treatment: interferon-sparing combinations.
    Gane E
    Liver Int; 2011 Jan; 31 Suppl 1():62-7. PubMed ID: 21205140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic hepatitis C: treatments of the future.
    Bourlière M; Khaloun A; Wartelle-Bladou C; Oules V; Portal I; Benali S; Adhoute X; Castellani P
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S84-95. PubMed ID: 22248700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational design of polymerase inhibitors as antiviral drugs.
    Oberg B
    Antiviral Res; 2006 Sep; 71(2-3):90-5. PubMed ID: 16820225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase.
    Delang L; Froeyen M; Herdewijn P; Neyts J
    Antiviral Res; 2012 Jan; 93(1):30-8. PubMed ID: 22033247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New nucleoside analogues in clinical development.
    Faderl S; Gandhi V; Kantarjian H; Plunkett W
    Cancer Chemother Biol Response Modif; 2002; 20():37-58. PubMed ID: 12703199
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.